Anti-angiogenic compositions and methods of use

TL;DR: In this article, the authors proposed an implantable medical device consisting of a structural element, wherein the structural element includes: a continuous phase comprising a first polymer, a discrete phase within the continuous phase, where the discrete phase has a second polymer including discrete phase segments; and anchor segments that have substantially the same chemical make up as the first polymer.

TL;DR: In this paper, self-emulsifying formulations and methods for delivering therapeutic agents to such tissues are described. But they do not discuss the use of such formulations for transplant rejection in a subject.

TL;DR: In this paper, formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations have been described.

TL;DR: In this article, the authors provide devices for treatment of a patient, wherein at least a portion of the device is provided with a biodegradable coating composed of multiple coated layers of biodegarable material.

TL;DR: It is shown that vascular endothelial growth factor (VEGF) probably functions as a hypoxia-inducible angiogenic factor and is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci and the clustering of capillaries alongside VEGF-producing cells.

TL;DR: The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.

TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.

TL;DR: Tumor ascites fluids from guinea pigs, hamsters, and mice contain activity that rapidly increases microvascular permeability, and this activity is secreted by these tumor cells and a variety of other tumor cell lines in vitro.